SEP 4, 2026 · PHASE 1 TRIAL
mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian
ClinicalTrials.gov
Phase 1b/II dose-escalation trial with planned enrollment and no results yet reported in this registry record; early-phase design focused on safety and maximum tolerated dose.
Reported
Planned enrollment159
PhasePhase 1b/II
Primary outcome measureMaximum tolerated dose, up to 28 days